The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Evaluating the emerging role of cellular therapies in GI cancers
David Bing Zhen, MD, University of Washington Medicine, Seattle, WA, comments on the future of cellular therapies in gastrointestinal malignancies. Despite CAR-T cell therapies having more success in hematological malignancies, recent strategies have enabled cellular immunotherapies across different modalities to be viable in solid tumors, such as targeting anti-claudin 18.2 in gastric cancer and elucidating novel biomarkers of efficacy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
